Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cisplatin-induced activation of the EGF receptor

Abstract

Cisplatin (CDDP) is an efficient DNA-damaging antitumor agent employed for the treatment of various human cancers. CDDP activates nuclear as well as cytoplasmatic signaling pathways involved in regulation of the cell cycle, damage repair and programmed cell death. Here we report that CDDP also activates a membrane-integrated protein, the epidermal growth factor receptor (EGFR). We show that EGFR is activated in response to CDDP in various types of cells that overexpress the receptor, including transformed human glioma cells and human breast tumor cells. CDDP-induced EGFR activation requires its kinase activity, as it can be blocked by an EGFR kinase inhibitor or by expression of a kinase dead receptor. We also show that CDDP-induced EGFR activation is independent of receptor ligand. CDDP induces the activation of c-Src, and EGFR activation is blocked by Src-family inhibitor PP1, suggesting that Src kinases mediate CDDP-induced EGFR activation. We propose that EGFR activation in response to CDDP is a survival response, since inhibition of EGFR activation enhances CDDP-induced death. These findings show that signals generated by DNA damage can modulate EGFR activity, and argue that interfering with CDDP-induced EGFR activation in tumor cells might be a useful approach to sensitize these cells to genotoxic agents.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

References

  • Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Tanaka M, Shiojima I, Hiroi Y, Yazaki Y . 1997 J. Clin. Invest. 100: 1813–1821

  • Benhar M, Dalyot I, Engelberg D, Levitzki A . 2001 Mol. Cell. Biol. 21: 6913–6926

  • Benhar M, Engelberg D, Levitzki A . 2002 EMBO Rep. 3: 420–425

  • Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ . 1999 J. Biol. Chem. 274: 8335–8343

  • Chen K, Vita JA, Berk BC, Keaney Jr JF . 2001 J. Biol. Chem. 276: 16045–16050

  • Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A . 1997 EMBO J. 16: 7032–7044

  • Deschesnes RG, Huot J, Valerie K, Landry J . 2001 Mol. Biol. Cell. 12: 1569–1582

  • Fang L, Li G, Liu G, Lee SW, Aaronson SA . 2001 EMBO J. 20: 1931–1939

  • Gebauer G, Mirakhur B, Nguyen Q, Shore SK, Simpkins H, Dhanasekaran N . 2000 Int. J. Oncol. 16: 321–325

  • Gibson S, Tu S, Oyer R, Anderson SM, Johnson GL . 1999 J. Biol. Chem. 274: 17612–17618

  • Haas M, Wang H, Tian J, Xie Z . 2002 J. Biol. Chem. 277: 18694–18702

  • Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA . 1996 J. Biol. Chem. 271: 695–701

  • Johnson GR, Kannan B, Shoyab M, Stromberg K . 1993 J. Biol. Chem. 268: 2924–2931

  • Jordan P, Carmo-Fonseca M . 2000 Cell. Mol. Life Sci. 57: 1229–1235

  • Kartalou M, Essigmann JM . 2001 Mutat. Res. 478: 23–43

  • Kitagawa D, Tanemura S, Ohata S, Shimizu N, Seo J, Nishitai G, Watanabe T, Nakagawa K, Kishimoto H, Wada T, Tezuka T, Yamamoto T, Nishina H, Katada T . 2001 J. Biol. Chem. 2: 2

  • Knebel A, Rahmsdorf HJ, Ullrich A, Herrlich P . 1996 EMBO J. 15: 5314–5325

  • Leu CM, Chang C, Hu C . 2000 Oncogene 19: 1665–1675

  • Lin RZ, Hu ZW, Chin JH, Hoffman BB . 1997 J. Biol. Chem. 272: 31196–31202

  • Luttrell LM, Della Rocca GJ, van Biesen T, Luttrell DK, Lefkowitz RJ . 1997 J. Biol. Chem. 272: 4637–4644

  • Maudsley S, Pierce KL, Zamah AM, Miller WE, Ahn S, Daaka Y, Lefkowitz RJ, Luttrell LM . 2000 J. Biol. Chem. 275: 9572–9580

  • Miyajima A, Nakashima J, Yoshioka K, Tachibana M, Tazaki H, Murai M . 1997 Br. J. Cancer 76: 206–210

  • Moro L, Dolce L, Cabodi S, Bergatto E, Erba EB, Smeriglio M, Turco E, Retta SF, Giuffrida MG, Venturino M, Godovac-Zimmermann J, Conti A, Schaefer E, Beguinot L, Tacchetti C, Gaggini P, Silengo L, Tarone G, Defilippi P . 2002 J. Biol. Chem. 277: 9405–9414

  • Moro L, Venturino M, Bozzo C, Silengo L, Altruda F, Beguinot L, Tarone G, Defilippi P . 1998 EMBO J. 17: 6622–6632

  • Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ . 1998 Proc. Natl. Acad. Sci. USA 95: 5724–5729

  • Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ . 1994 Proc. Natl. Acad. Sci. USA 91: 7727–7731

  • Osherov N, Levitzki A . 1994 Eur. J. Biochem. 225: 1047–1053

  • Pandey P, Raingeaud J, Kaneki M, Weichselbaum R, Davis RJ, Kufe D, Kharbanda S . 1996 J. Biol. Chem. 271: 23775–23779

  • Parsons JT, Parsons SJ . 1997 Curr. Opin. Cell. Biol. 9: 187–192

  • Pearce AK, Humphrey TC . 2001 Trends Cell. Biol. 11: 426–433

  • Persons DL, Yazlovitskaya EM, Cui W, Pelling JC . 1999 Clin. Cancer Res. 5: 1007–1014

  • Sato K, Sato A, Aoto M, Fukami Y . 1995 Biochem. Biophys. Res. Commun. 215: 1078–1087

  • Shiloh Y . 2001 Curr. Opin. Genet. Dev. 11: 71–77

  • Simizu S, Takada M, Umezawa K, Imoto M . 1998 J. Biol. Chem. 273: 26900–26907

  • Stoll SW, Benedict M, Mitra R, Hiniker A, Elder JT, Nunez G . 1998 Oncogene 16: 1493–1499

  • Tice DA, Biscardi JS, Nickles AL, Parsons SJ . 1999 Proc. Natl. Acad. Sci. USA 96: 1415–1420

  • Wang X, Martindale JL, Holbrook NJ . 2000a J. Biol. Chem. 275: 39435–39443

  • Wang X, McCullough KD, Franke TF, Holbrook NJ . 2000b J. Biol. Chem. 275: 14624–14631

  • Wu W, Graves LM, Gill GN, Parsons SJ, Samet JM . 2002 J. Biol. Chem. 277: 24252–24257

  • Xu W, Doshi A, Lei M, Eck MJ, Harrison SC . 1999 Mol. Cell. 3: 629–638

  • Yoshizumi M, Abe J, Haendeler J, Huang Q, Berk BC . 2000 J. Biol. Chem. 275: 11706–11712

  • Young MA, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J . 2001 Cell 105: 115–126

  • Zhou BB, Elledge SJ . 2000 Nature 408: 433–439

Download references

Acknowledgements

This study was supported by the Ministry of Science of the state of Israel and by the Israel Cancer Association through the estate of the late Alexander Smidoda.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alexander Levitzki.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Benhar, M., Engelberg, D. & Levitzki, A. Cisplatin-induced activation of the EGF receptor. Oncogene 21, 8723–8731 (2002). https://doi.org/10.1038/sj.onc.1205980

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205980

Keywords

  • cisplatin
  • EGF receptor
  • Src
  • Glioblastoma
  • DNA damage

This article is cited by

Search

Quick links